VTRS · Viatris Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Viatris reported Q2 2026 revenue of $3.8B (+3.5% operational), Adjusted EBITDA of $1.2B (+8% operational), and Adjusted EPS of $0.69 (+9% operational), driven by Greater China growth and U.S. complex generics/transdermals, and raised 2026 guidance midpoints across all key metrics while continuing to face Nashik facility supply disruptions expected to weigh $100–150M on 2H revenue.
- + Raised 2026 guidance midpoints across total revenues, Adjusted EBITDA, Adjusted EPS, and free cash flow.
- + Q2 total revenues grew 3.5% operationally to $3.8B with Adjusted EBITDA up 8% operationally to $1.2B and Adjusted EPS of $0.69.
- + FDA approved Gwyn Lo (combined hormonal contraceptive patch) with launch expected later this year.
- + Returned approximately $550M to shareholders year-to-date and reduced gross leverage to 2.9x, below midpoint of 2.8–3.2x target.
- + Pipeline progressing with multiple near-term catalysts including FDA-accepted NDA for fast-acting meloxicam (PDUFA Dec 27, 2026) and positive Phase 3 Nefecon data in Japan.
- − Reported U.S. GAAP net loss of $119M in Q2, primarily driven by a $177.8M non-cash charge on the planned Tyrvaya divestiture.
- − China procurement policy change expected to negatively impact hospital channel volumes in 2H 2026, with growth expected to moderate.
- − Additional competitive pressure expected in North America for products including Brena and Wixella in 2H 2026.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 4.4B | Twelve Months Ended June 30, 2026 | — |
| Adjusted EPS non-GAAP | $1.28 | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Margin non-GAAP | 56.8% | Six Months Ended June 30, 2026 | — |
| Adjusted gross margins non-GAAP | 57% | the three months ended June 30, 2026 filing | — |
| Capital returned to shareholders | $550M | Through August 5, 2026 | — |
| Consolidated total revenues at constant currency non-GAAP | $3.71B | the three months ended June 30, 2026 filing | — |
| Free Cash Flow non-GAAP | $677.4M | Six Months Ended June 30, 2026 | — |
| Gross debt to adjusted EBITDA non-GAAP | 2.9 | Twelve Months Ended June 30, 2026 | — |
| Net sales - Developed Markets | $2.19B | the three months ended June 30, 2026 filing | — |
| Net sales - Emerging Markets | $542.3M | the three months ended June 30, 2026 filing | — |
| Net sales - Greater China | $713.8M | the three months ended June 30, 2026 filing | +21.2% |
|
|
|||
| Net sales - JANZ | $296.1M | the three months ended June 30, 2026 filing | — |
| Net sales within North America | 882.7M | the three months ended June 30, 2026 filing | — |
| New product revenues | $172M | Six Months Ended June 30, 2026 | — |
| Share repurchases | $270M | Through August 5, 2026 | — |
| Total net sales | $3.75B | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VTRS
this stock
Viatris Inc
|
$20.48B | +42.3% | -3.0% | — | 3.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +16.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -4.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.9% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -11.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VTRS | +3.5% | +6.6% | +30.2% | +7.3% | +42.3% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +4.2% | +6.4% | +18.0% | +7.9% | +30.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.